Adcytherix Doses First Patient in Phase 1 Trial of ADCX-020 and Strengthens Leadership to Support Next Phase of GrowthInitial patient dosed in ...

Nurix Therapeutics, Inc. has announced a webcast conference call scheduled for June 12, 2025, at 8:00 a.m. ET to discuss new data from its ongoing Phase 1 clinical trial of bexobrutideg (NX-5948), ...

Rationale and study design of the KOV-HIPEC-02R (RECOVER): A randomized, multicenter, open-label phase III trial of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in ...

By David Bautz, PhD NASDAQ: MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Phase 1 Part 3 Trial of DA-1726 to ...